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– Education and training
– Ethics
The GCCP documents formed a major basis for a GLP adviso-
ry document for in vitro studies published by the OECD (2005).
In 2007, following the increasing use of technologies to culture 
human embryonic and pluripotent stem cells, the ECVAM Task 
Force was re-formed to produce a special supplementary GCCP 
document on considerations for good practice in the culture of 
human pluripotent stem cells “Human embryonic stem cell (hESC) 
technology for toxicology and drug development: summary of 
current status and recommendations for best practice and stan-
dardization. The Report and Recommendations of an ECVAM 
Workshop”1 . 
More recently, two OECD working groups proposed a revision 
of GCCP and a series of taskforce workshops were held around 
the world to consider the needs for new GCCP principles to ad-
dress the new cellular, molecular and engineering tools, which had 
come into common use since 2005. This led to an OECD Guid-
ance Document on Good In Vitro Method Practices (GIVIMP) 
(OECD, 2018). The guidance cross-references and appends the 
at that time available GCCP documents (Eskes et al., 2017). 
Under the leadership of the Johns Hopkins Center for Alter-
natives to Animal Testing (CAAT), two workshops were held in 
2015 in Baltimore, USA, and Konstanz, Germany, as part of the 
Introduction
Following the organization of a first symposium on Good Cell 
Culture Practice (GCCP) for the German Society for Cell Biol-
ogy (DGZ) in 1996 by Thomas Hartung, teaming up with Ger-
hard Gstraunthaler, the 3rd World Conference on  on Alternatives 
and Animal Use in the Life Sciences in Bologna, Italy, in 1999 
took up this topic. Discussing challenges in the performance of 
reliable in vitro studies using cells and tissues led to the Bologna 
declaration toward GCCP (Gstraunthaler and Hartung, 1999). 
“The participants … call on the scientific community to de-
velop guidelines defining minimum standards in cell and tis-
sue culture, to be called Good Cell Culture Practice … should 
facilitate the interlaboratory comparability of in vitro results … 
encourage journals in the life sciences to adopt these guide-
lines...”
The European Centre for the Validation of Alternative Methods 
(ECVAM) of the European Commission then established a task-
force to generate a Good Cell Culture Practice guidance document 
that would address the key principles required to assure repro- 
ducibility and quality of in vitro (cell-based) assays (Hartung et 
al., 2002). The ECVAM task force of cell biologists drawn from 
academic research, industry and safety testing backgrounds pub-
lished the first GCCP principles of best practice in 2005 (Coecke 
et al., 2005). GCCP addresses issues related to:
– Characterization & maintenance of essential characteristics
– Quality assurance
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ment for quantified characterization of cells to facilitate the es-
tablishment of meaningful acceptance criteria to help assure a 
better defined in vitro culture state, reduced variation of cultures, 
and improved accuracy of cell culture-derived data.
Parallel work on Good In Vitro Reporting Standards (GIVReSt) 
(Hartung et al., 2019; Krebs et al., 2019) also has been incorpo-
rated, but this work will continue under the auspices of the CAAT 
GCCP working group. 
 
The GCCP 2.0 open consultation and review process
The draft GCCP 2.0 manuscript is hereby published for public 
comment as supplement2 to this article. Over the last few years, a 
Scientific Advisory Committee (SAC GCCP 2.0) has been formed. 
We invite all interested stakeholders to join the SAC. Applicants 
will be able to apply from the day of the publication of this paper 
and are expected to be bona fide cell culture practitioners. Please 
send an email to: CAAT@jhu.edu
All members of the SAC will have the opportunity to suggest 
revisions of the text, starting beginning of September 2020, end-
ing end of November 2020. On acceptance, the new SAC mem-
bers will receive a commentary template to utilize. Comments 
will only be considered when accompanied by a specific line 
number reference in the manuscript and a proposal for a specif-
ic change to the text and completed templates. The platform for 
this process is under development and will be communicated to 
the SAC volunteers.
All SAC members will be able to vote on the revisions sug-
gested in December 2020. At the beginning of 2021, following 
a final revision by the steering group, the guidance will be pub-
lished, and a number of dissemination activities will be started. 
It is hoped that this public consultation will assure an open and 
scientifically intense review of GCCP 2.0 across cell culture ex-
perts in various fields of research, in vitro testing, biotechnology 
development and industry. The GCCP 2.0 steering group has de-
veloped a dissemination plan, which will be activated before the 
public release of GCCP 2.0 and will include consultation with 
journal editors and life science funding organizations. Further-
more, the new extended SAC will be asked to propose and assist 
with future dissemination opportunities. 
The final publication will hopefully provide a go-to good prac-
tice reference for students, those coming to use cell culture for 
the first time or existing cell culture practitioners wishing to use 
new cell culture systems. The establishment and implementation 
of the revised guidance promises to improve the quality of re-
search for an important part of the toolbox in the life sciences. 
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